A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues  

作　　者：Chunyan Yi Zhiyang Ling Xiao Lu Yadong Fu Zhuo Yang Sonam Wangmo Shuangfeng Chen Yaguang Zhang Liyan Ma Wangpeng Gu Hongzhou Lu Xiaoyu Sun Bing Sun 

机构地区：[1]State Key Laboratory of Cell Biology,Shanghai Institute of Biochemistry and Cell Biology,Center for Excellence in Molecular Cell Science,Chinese Academy of Sciences,University of Chinese Academy of Sciences,Shanghai,200031,China [2]School of Life Science and Technology,ShanghaiTech University,Shanghai,201210,China [3]National Clinical Center for Infectious Disease,The Third People’s Hospital of Shenzhen and the Second Affiliated Hospital of Southern University of Science and Technology,Shenzhen,518112,Guangdong Province,China [4]Shanghai Public Health Clinical Center,Shanghai Medical College,Fudan University,Shanghai,201508,China

出　　处：《Cellular & Molecular Immunology》2022年第5期647-649,共3页中国免疫学杂志（英文版）

基　　金：supported by the Ministry of Science and Technology of China (2018YFA0507402);the National Natural Science Foundation of China (32100123,32100751,and 82041015).

摘　　要：The newly emerged Omicron(B.1.1.529)variant of SARS-CoV-2 is quickly overtaking the Delta variant and becoming the dominant strain around the world due to its enhanced transmissibility and high immune escape potential[1,2].Compared to the Wuhan strain,the Omicron variant carries 37 spike mutations,of which 15 are within the receptor-binding domain(RBD)(Fig.1A).A high mutation rate is associated with remarkable resistance to current vaccines and RBD-specific antibody therapeutics[2,3,4].

关 键 词：RESIDUES BECOMING OMI 

分 类 号：R392[医药卫生—免疫学]